Cargando…

Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A

The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituximab. Through a central patho...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Tomohiro, Watanabe, Takashi, Itoh, Kuniaki, Yoshimura, Kenichi, Tobinai, Kensei, Ogura, Michinori, Yamaguchi, Motoko, Kurosawa, Mitsutoshi, Imaizumi, Yoshitaka, Ota, Shuichi, Kaba, Harumi, Mukai, Kiyoshi, Nakamura, Shigeo, Ohshima, Koichi, Hotta, Tomomitsu, Tsukasaki, Kunihiro, Nagai, Hirokazu, Shimoyama, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JSLRT 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053572/
https://www.ncbi.nlm.nih.gov/pubmed/33731548
http://dx.doi.org/10.3960/jslrt.20062
_version_ 1783680151116054528
author Kinoshita, Tomohiro
Watanabe, Takashi
Itoh, Kuniaki
Yoshimura, Kenichi
Tobinai, Kensei
Ogura, Michinori
Yamaguchi, Motoko
Kurosawa, Mitsutoshi
Imaizumi, Yoshitaka
Ota, Shuichi
Kaba, Harumi
Mukai, Kiyoshi
Nakamura, Shigeo
Ohshima, Koichi
Hotta, Tomomitsu
Tsukasaki, Kunihiro
Nagai, Hirokazu
Shimoyama, Masanori
author_facet Kinoshita, Tomohiro
Watanabe, Takashi
Itoh, Kuniaki
Yoshimura, Kenichi
Tobinai, Kensei
Ogura, Michinori
Yamaguchi, Motoko
Kurosawa, Mitsutoshi
Imaizumi, Yoshitaka
Ota, Shuichi
Kaba, Harumi
Mukai, Kiyoshi
Nakamura, Shigeo
Ohshima, Koichi
Hotta, Tomomitsu
Tsukasaki, Kunihiro
Nagai, Hirokazu
Shimoyama, Masanori
author_sort Kinoshita, Tomohiro
collection PubMed
description The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituximab. Through a central pathological review, 829 patients were diagnosed with BCL according to the World Health Organization classification and treated with doxorubicin-containing combination chemotherapies. Of these patients, 642, 104, 30, and 24 patients were diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL), respectively. The overall survival (OS) of FL and MZL patients was higher than that of patients with DLBCL and MCL. The OS of the MCL patients was higher than that of DLBCL patients in the first 5 years, but MCL had the lowest survival after 5 years. The OS of DLBCL patients was clearly stratified by the international prognostic index and showed data compatible with that of aggressive lymphoma in the pre-rituximab era. These results established the clinical aspects of BCL in a large number of patients treated in prospective studies during the pre-rituximab era in Japan.
format Online
Article
Text
id pubmed-8053572
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher JSLRT
record_format MEDLINE/PubMed
spelling pubmed-80535722021-04-19 Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A Kinoshita, Tomohiro Watanabe, Takashi Itoh, Kuniaki Yoshimura, Kenichi Tobinai, Kensei Ogura, Michinori Yamaguchi, Motoko Kurosawa, Mitsutoshi Imaizumi, Yoshitaka Ota, Shuichi Kaba, Harumi Mukai, Kiyoshi Nakamura, Shigeo Ohshima, Koichi Hotta, Tomomitsu Tsukasaki, Kunihiro Nagai, Hirokazu Shimoyama, Masanori J Clin Exp Hematop Original Article The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituximab. Through a central pathological review, 829 patients were diagnosed with BCL according to the World Health Organization classification and treated with doxorubicin-containing combination chemotherapies. Of these patients, 642, 104, 30, and 24 patients were diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL), respectively. The overall survival (OS) of FL and MZL patients was higher than that of patients with DLBCL and MCL. The OS of the MCL patients was higher than that of DLBCL patients in the first 5 years, but MCL had the lowest survival after 5 years. The OS of DLBCL patients was clearly stratified by the international prognostic index and showed data compatible with that of aggressive lymphoma in the pre-rituximab era. These results established the clinical aspects of BCL in a large number of patients treated in prospective studies during the pre-rituximab era in Japan. JSLRT 2021-03-18 /pmc/articles/PMC8053572/ /pubmed/33731548 http://dx.doi.org/10.3960/jslrt.20062 Text en © 2021 by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License.
spellingShingle Original Article
Kinoshita, Tomohiro
Watanabe, Takashi
Itoh, Kuniaki
Yoshimura, Kenichi
Tobinai, Kensei
Ogura, Michinori
Yamaguchi, Motoko
Kurosawa, Mitsutoshi
Imaizumi, Yoshitaka
Ota, Shuichi
Kaba, Harumi
Mukai, Kiyoshi
Nakamura, Shigeo
Ohshima, Koichi
Hotta, Tomomitsu
Tsukasaki, Kunihiro
Nagai, Hirokazu
Shimoyama, Masanori
Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
title Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
title_full Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
title_fullStr Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
title_full_unstemmed Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
title_short Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
title_sort clinical characteristics of patients with b-cell lymphoma enrolled in clinical trials for aggressive lymphoma in japan: japan clinical oncology group - lymphoma study group study – jcog0108a
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053572/
https://www.ncbi.nlm.nih.gov/pubmed/33731548
http://dx.doi.org/10.3960/jslrt.20062
work_keys_str_mv AT kinoshitatomohiro clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT watanabetakashi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT itohkuniaki clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT yoshimurakenichi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT tobinaikensei clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT oguramichinori clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT yamaguchimotoko clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT kurosawamitsutoshi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT imaizumiyoshitaka clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT otashuichi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT kabaharumi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT mukaikiyoshi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT nakamurashigeo clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT ohshimakoichi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT hottatomomitsu clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT tsukasakikunihiro clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT nagaihirokazu clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a
AT shimoyamamasanori clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a